ALX Oncology Holdings Inc.NASDAQ: ALXO

ALX Oncology to Present at Upcoming Investor Conferences

· Issued by ALX Oncology Holdings Inc. via GlobeNewswire

Summary by 6ix AI

ALX Oncology, a clinical-stage biotechnology company developing cancer therapies, said its leadership will take part in fireside chats (informal on-stage interviews) and one-on-one meetings at three investor conferences between November 17, 2026 and December 1, 2026.

Key details

  • UBS London Healthcare Conference in London, UK: fireside chat on Tuesday, November 17, 2026 at 4:40 PM GMT / 11:40 AM EST.
  • Jefferies London Healthcare Conference in London, UK: fireside chat on Wednesday, November 18, 2026 at 1:00 PM GMT / 8:00 AM EST.
  • Piper Sandler Annual Healthcare Conference in New York, NY: fireside chat on Tuesday, December 1, 2026 at 3:30 PM EST.
  • Webcasts of the fireside chats can be accessed in the Investors section of www.alxoncology.com, and replays will be archived for up to 90 days after each presentation date.

6ix AI wrote this summary from the release below and checked it against the release.

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.

The details of the meetings are as follows:

UBS London Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Tuesday, November 17, 2026
Location: London, UK
Time of Fireside Chat Presentation: 4:40 PM GMT / 11:40 AM EST
Webcast Link: Available here

Jefferies London Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Wednesday, November 18, 2026
Location: London, UK
Time of Fireside Chat Presentation: 1:00 PM GMT / 8:00 AM EST
Webcast Link: Available here

Piper Sandler Annual Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Tuesday, December 1, 2026
Location: New York, NY
Time of Fireside Chat Presentation: 3:30 PM EST
Webcast Link: Available here

The webcasts of the fireside chats can be accessed through the links above or by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replays of the webcasts will be archived for up to 90 days following the presentation dates.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn.

Investor Relations Contact:
Kevin Lui
Director, Investor Relations
kevin.lui@precisionaq.com

Media Contact:
Genevieve Britton
Senior Director, Public Relations
genevieve.britton@precisionaq.com

View original source (GlobeNewswire)ALX Oncology Holdings Inc. on 6ix

Story so far

Earlier from ALX Oncology

Later from ALX Oncology

All ALX Oncology news releases